Fast and slow metabolizers of hoasca

Journal of Psychoactive Drugs

Volumn 37, Issue 2, 2005, Pages 157-161

  Callaway, J C ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Alkaloid; Ayahuasca; CYP 2D6; Hoasca; MAO; Metabolism; Polymorphism

Indexed keywords

BANISTERIOPSIS CAAPI EXTRACT; CYTOCHROME P450 2D6; CYTOCHROME P450 INHIBITOR; HARMINE; HOASCA; MONOAMINE OXIDASE A INHIBITOR; PLANT EXTRACT; UNCLASSIFIED DRUG;

BANISTERIOPSIS; BANISTERIOPSIS CAAPI; BEVERAGE; DRUG EXCRETION; DRUG METABOLISM; GENETIC POLYMORPHISM; PHENOTYPE; REVIEW;

AREA UNDER CURVE; BANISTERIOPSIS; CYTOCHROME P-450 CYP2D6; HARMALINE; HARMINE; HUMANS; N,N-DIMETHYLTRYPTAMINE; PHENOTYPE; PLANT EXTRACTS; PLANTS; TIME FACTORS;

EID: 23344439346     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.2005.10399797     Document Type: Article

References (27)

1. Benedetti, M.S. 2001. Biotransformation of xenobiotics by amine oxidases. Fundamental and Clinical Pharmacology 15 (2): 75-84.
2. Bourin, M.; Chue, P. &Guillon, Y. 2001. Paroxetine: A review. CNS Drug Review 7 (1): 25-47.
3. Bradford, L.D. 2002. CYP2D6 allele frequency in European Caucasuans, Asians, Africans and their descendants. Pharmacogenomics 3 (2): 229-43.
4. Callaway, J.C. 2005. Various alkaloid profiles in decoctions of Banisteriopsis caapi. Journal of Psychoactive Drugs (in this issue).
5. Callaway, J.C. 1988. A proposed mechanism for the visions of dream sleep. Medical Hypotheses 26: 119-24.
6. Callaway, J.C. &Grob, C.S. 1998. Ayahuasca preparations and serotonin reuptake inhibitors: A potential combination foradverse interaction. Journal of Psychoactive Drugs 30 (4): 367-69.
7. Callaway, J.C.; Brito, G.S. &Neves, E.S. 2005. Phytochemical analyses of Banisteropsis caapi and Psychotria viridis. Journal of Psychoactive Drugs (in this issue).
8. Callaway, J.C.; McKenna, D.J.; Grob, C.S.; Brito, G.S.; Raymon, L.P.; Poland, R.; Andrade, E.N. &Andrade, E.O. 1999. Pharmacology of hoasca alkaloids in healthy humans. Journal of Ethnopharmacology 6 (3): 243-56.
9. Callaway, J.C.; Raymon, L.P.; He, W.L.; McKenna, D.J.; Grob, C.S. &Brito, G.S. 1996. Quantitation of N, N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca. Journal of Analytical Toxicology 20: 492-97.
10. Callaway, J.C.; Gynther, J.; Poso, A.; Vepsalainen, J. &Airaksinen, M.M. 1994a. The Pictet-Spengler reaction and biogenic tryptamines: Formation of tetrahydro-P-carbolines at physiological pH. Journal of Heterocyclic Chemistry 31: 431-435.
11. Callaway, J.C.; Airaksinen, M.M.; McKenna, D.J.; Brito, C.S. &Grob, C.S. 1994b. Platelet serotonin uptake sites increased in drinkers of ayahuasca. Psychopharmacology 116: 385-87.
12. Christensen, M.; Andersson, K.; Dalen, P.; Mirghani, R.A.; Muirhead, G.J.; Nordmark, A.; Tybring, G.; Wahlberg, A.; Yasar, U. &Bertilsson, L. 2003. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clinical Pharmacology and Therapeutics 73 (6): 517-28.
13. Dahl, M.L. 2002. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: Useful aid to prescribing? Clinical Pharmacokinetics 41 (7): 453-70.
14. Eichelbaum, M. 2003. In search of endogenous CYP2D6 substrates. Pharmacogenetics 13:305-06.
15. Grob, C.S.; McKenna, D.J.; Callaway, J.C.; Brito, G.S.; Neves, E.S.; Oberlander, G.; Saide, O.L.; Labigalini, E.; Tacla, C.; Miranda, C.T.; Strassman, R.J. & Boone, K.B. 1996. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brasil. Journal of Nervous and Mental Disease 184 (2): 86-94.
16. Holmstedt, B.R. & Lindgren, J-E. 1967. Chemical constituents and pharmacology of South American snuffs. In: D.H. Efron; B. Holmstedt &N.S. Kline (Eds.) Ethnopharmacologic Search for Psychoactive Drugs (No. 1645) Washington, D.C.: U.S. Public Health Service.
17. Hryhorczuk, L.M.; Rainey, J.M.; Froham, C.E. & Novak, E.A. 1986. A new metabolic pathway for N, N-dimethyltryptamine. Biological Psychiatry 21 (I): 84-93.
18. Kim, H; Sablin, S.O. & Ramsay, R.R. 1997. Inhibition of monoamine oxidase A by beta-carboline derivatives. Archives of Biochemistry and Biophysics 337 (1): 137-42.
19. McKenna, D.J.; Callaway, J.C. & Grob, C.S. 1998. The scientific investigation of ayahuasca: A review of past and current research. Heffter Review of Psychedelic Research I: 65-77.
20. Mahgoub, A.; Idle, J.R.; Drig, L.G.; Lancaster, R. & Smith, R.L. 1977. Polymorphic hydroxylation of debrisoquine in man. Lancet 2: 584-86.
21. Oscarson, M. 2003. Pharmacogenetics of drug metabolizing enzymes: Importance for personalized medicine. Clinical Chemistry and Laboratory Medicine 41 (4): 573-80.
22. Riba, J.; Valle, M.; Urbano, G.; Yritia, M.; Morte, A. & Barbanoj, M.J. 2003. Human pharmacology of ayahuasca: Subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics 306: 73-83.
23. Tiihonen, J.; Pesonen, U.; Kauhanen, J.; Koulu, M.; Hallikainen, T.; Leskinen, L. & Salonen, J.T. 2000. CYP2A6 genotype and smoking. Molecular Pharmacology 5: 347.
24. Wilbert, J. 1991. Does pharmacology corroborate the nicotine therapy and practices of South American shamanism? Journal of Ethnopharmacology 32: 179-86.
25. Yu, A.M.; Idle, J R. & Gonzales, F.J. 2004. Polymorphic cytochrome P450 2D6: Humanized mouse model and endogenous substrates. Drug Metabolism Reviews 36 (2): 243-77.
26. Yu, A.M.; Idle, J.R.; Herrazi, T.; Kiipfer, A. & Gonzalez, F.J. 2003a. Screening for endoganous substrates reveals that CYP2D6 is a 5-methoxyindolethylamine O-demethylase. Pharmacogenetics 13: 307-19.
27. Yu, A.M.; Idle, J.R.; Krausz, K.W.; Kiipfer, A. & Gonzales, F.J. 2003b. Contribution of individual cytochrome p450 isozymes to the O-demethylation of the psychotropic beta-carboline alkaloids harmaline and harmine. Journal of Pharmacology andExperimental Therapeutics 305 (1): 315-22.